Basic endocrine products of adipose tissue in states of thyroid dysfunction

Thyroid

Volumn 17, Issue 5, 2007, Pages 421-431

  Pontikides, Nikolaos ^a   Krassas, Gerasimos E ^a  

^a PANAGIA GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CYTOKINE; GROWTH FACTOR; HORMONE DERIVATIVE; INTERLEUKIN 6; PEPTIDE DERIVATIVE; RESISTIN; THYROID HORMONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; BODY WEIGHT; CENTRAL NERVOUS SYSTEM; ENERGY EXPENDITURE; HORMONE RELEASE; HUMAN; LIVER; NONHUMAN; PANCREAS; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; THYROID DISEASE; THYROID FUNCTION;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; INTERLEUKIN-6; RESISTIN; THYROID GLAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34249949583     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0016     Document Type: Review

References (82)

1. Haque WA, Garg A 2004 Adipocyte biology and adipocytokines. Clin Lab Med 24:217-234.
2. Feldt-Rasmussen U 2007 Thyroid and leptin. Thyroid (submitted).
3. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF 1995 A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746-26749.
4. Hu E, Liang P, Spiegelman BM 1996 AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697-10703.
5. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K 1996 cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286-289.
6. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M 1996 Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 120:803-812.
7. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y 1999 Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83.
8. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T 2003 Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769.
9. Hegele RA, Cao H, Huff MW, Anderson CM 2000 LMNA R482Q mutation in partial lipodystrophy associated with reduced plasma leptin concentration. J Clin Endocrinol Metab 85:3089-3093.
10. Statnick MA, Beavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD, Rafaeloff-Phail R, Seng T, Suter TM, Sluka JP, Ravussin E, Gadski RA, Caro JF 2000 Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res 1:81-88.
11. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y 2000 Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599.
12. Chandran M, Phillips SA, Ciaraldi T, Henry RR 2003 Adiponectin: more than just another fat cell hormone? Diabetes Care 26:2442-2450.
13. Diez JJ, Iglesias P 2003 The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148:293-300.
14. Kinlaw WB, Marsh B 2004 Adiponectin and HIV-lipodystrophy: taking HAART. Endocrinology 145:484-486.
15. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y; Osaka CAD Study Group 2003 Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85-89.
16. Yoda M, Nakano Y, Tobe T, Shioda S, Choi-Miura NH, Tomita M 2001 Characterization of mouse GBP28 and its induction by exposure to cold. Int J Obes Relat Metab Disord 25:75-83.
17. Fernandez-Real JM, Lopez-Bermejo A, Casamitjana R, Ricart W 2003 Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab 88:2714-2718.
18. Bakker SJ, ter Maaten JC, Popp-Snijders C, Slaets JP, Heine RJ, Gans RO 2001 The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab 86:1206-1211.
19. Iglesias P, Alvarez Fidalgo P, Codoceo R, Diez JJ 2003 Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. Clin Endocrinol (Oxf) 59:621-629.
20. Santini F, Marsili A, Mammoli C, Valeriano R, Scartabelli G, Pelosini C, Giannetti M, Centoni R, Vitti P, Pinchera A 2004 Serum concentrations of adiponectin and leptin in patients with thyroid dysfunctions. J Endocrinol Invest 27:RC5-RC7.
21. Yaturu S, Prado S, Grimes SR 2004 Changes in adipocyte hormones leptin, resistin, and adiponectin in thyroid dysfunction. J Cell Biochem 93:491-496.
22. Saito T, Kawano T, Saito T, Ikoma A, Namai K, Tamemoto H, Kawakami M, Ishikawa SE 2005 Elevation of serum adiponectin levels in Basedow disease. Metabolism 54:1461-1466.
23. Altinova AE, Toruner FB, Akturk M, Bukan N, Cakir N, Ayvaz G, Arslan M 2006 Adiponectin levels and cardiovascular risk factors in hypothyroidism and hyperthyroidism. Clin Endocrinol (Oxf) 65:530-535.
24. Yu HY, Yang Y, Zhang MX, Lu HL, Zhang JH, Wang HW, Cianflone K 2006 Thyroid status influence on adiponectin, acylation stimulating protein and complement C3 in hyperthyroid and hypothyroid subjects. Nutr Metab (Lond) 3:13.
25. Loustis K, Pontikides N, Koliakos G, Constantinidis Th, Papadopoulou F, Krassas GE 2006 Serum cytokines profile in Graves' hyperthyroidism before and after restoration of thyroid function: correlation with different anthropometric parameters. Proceedings of the 31st European Thyroid Association meeting, Naples, P143, 96.
26. Pontikides N, Loustis K, Koliakos G, Constantinidis Th, Kaltsas Th, Krassas GE 2006 Serum cytokines levels in hypothyroidism before and after treatment: relationship with body weight and body composition. Proceedings of the 31st European Thyroid Association meeting, Naples, P144, 97.
27. Botella-Carretero JI, Alvarez-Blasco F, Sancho J, Escobar-Morreale HF 2006 Effects of thyroid hormones on serum levels of adipokines as studied in patients with differentiated thyroid carcinoma during thyroxine withdrawal. Thyroid 16:397-402.
28. Papanicolaou DA, Vgontzas AN 2000 Interleukin-6: the endocrine cytokine. J Clin Endocrinol Metab 85:1331-1333.
29. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP 1998 The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 128:127-137.
30. Stouthard JM, Romijn JA, Van der Poll T, Endert E, Klein S, Bakker PJ, Veenhof CH, Sauerwein HP 1995 Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol 268:E813-E819.
31. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW 1997 Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196-4200.
32. Fried SK, Bunkin DA, Greenberg AS 1998 Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83:847-850.
33. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B 2000 Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85:3338-3342.
34. Koerner A, Kratzsch J, Kiess W 2005 Adipocytokines: leptin - the classical, resistin - the controversial, adiponectin - the promising, and more to come. Best Pract Res Clin Endocrinol Metab 19:525-546.
35. Hotamisligil GS, Shargill NS, Spiegelman BM 1993 Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91.
36. Van der Poll T, Romijn JA, Endert E, Borm JJ, Buller HR, Sauerwein HP 1991 Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol 261:E457-E465.
37. Sethi JK, Hotamisligil GS 1999 The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 10:19-29.
38. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW 2004 Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145:2273-2282.
39. Wajchenberg BL 2000 Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21:697-738.
40. Ruan H, Lodish HF 2003 Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 14:447-455.
41. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, Frantz GD, Tumas DB, Peale FV Jr, Shelton DL, Hebert CC 2000 FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 19:4046-4055.
42. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA 2001 The hormone resistin links obesity to diabetes. Nature 409:307-312.
43. Kim KH, Lee K, Moon YS, Sul HS 2001 A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 276:11252-11256.
44. Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L 2004 Disulfide-dependent multimeric assembly of resistin family hormones. Science 304:1154-1158.
45. Kusminski CM, McTernan PG, Kumar S 2005 Role of resistin in obesity, insulin resistance and Type II diabetes. Clin Sci (Lond) 109:243-256.
46. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA 2004 An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 1:E45.
47. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S 2001 Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 50:2199-2202.
48. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S 2002 Resistin, central obesity, and type 2 diabetes. Lancet 359:46-47.
49. Utzschneider KM, Carr DB, Tong J, Wallace TM, Hull RL, Zraika S, Xiao Q, Mistry JS, Retzlaff BM, Knopp RH, Kahn SE 2005 Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 48:2330-2333.
50. Krassas GE, Pontikides N, Loustis K, Koliakos G, Constantinidis T, Kaltsas T 2006 Resistin levels are normal in hypothyroidism and remain unchanged after attainment of euthyroidism: relationship with insulin levels and anthropometric parameters. J Endocrinol Invest 29:606-612.
51. Nogueiras R, Gualillo O, Caminos JE, Casanueva FF, Dieguez C 2003 Regulation of resistin by gonadal, thyroid hormone, and nutritional status. Obes Res 11:408-414.
52. Krassas GE, Pontikides N, Loustis K, Koliakos G, Constantinidis T, Panidis D 2005 Resistin levels in hyperthyroid patients before and after restoration of thyroid function: relationship with body weight and body composition. Eur J Endocrinol 153:217-221.
53. Bartalena L, Brogioni S, Grasso L, Velluzzi F, Martino E 1994 Relationship of the increased serum interleukin-6 concentration to changes of thyroid function in nonthyroidal illness. J Endocrinol Invest 17:269-274.
54. Bartalena L, Grasso L, Brogioni S, Aghini-Lombardi F, Braverman LE, Martino E 1994 Serum interleukin-6 in amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 78:423-427.
55. Celik I, Akalin S, Erbas T 1995 Serum levels of interleukin 6 and tumor necrosis factor-alpha in hyperthyroid patients before and after propylthiouracil treatment. Eur J Endocrinol 132:668-672.
56. Murai H, Murakami S, Ishida K, Sugawara M 1996 Elevated serum interleukin-6 and decreased thyroid hormone levels in postoperative patients and effects of IL-6 on thyroid cell function in vitro. Thyroid 6:601-606.
57. Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, Minelli R, Braverman LE, Roti E 1996 Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. J Clin Endocrinol Metab 81:2976-2979.
58. Komorowski J, Jankiewicz J, Robak T, Blasinska-Morawiec M, Stepien H 1998 Cytokines serum levels as the markers of thyroid activation in Graves' disease. Immunol Lett 60:143-148.
59. Ahmad L, Parkes A, Lazarus J, Bartalena L, Martino E, Diamond E, Stagnaro-Green A 1998 Interleukin-6 levels are not increased in women with postpartum thyroid dysfunction. Thyroid 8:371-375.
60. Siddiqi A, Monson JP, Wood DF, Besser GM, Burrin JM 1999 Serum cytokines in thyrotoxicosis. J Clin Endocrinol Metab 84:435-439.
61. Jones BM, Kwok CC, Kung AW 1999 Effect of radioactive iodine therapy on cytokine production in Graves' disease: transient increases in interleukin-4 (IL-4), IL-6, IL-10, and tumor necrosis factor-alpha, with longer term increases in interferon-gamma production. J Clin Endocrinol Metab 84:4106-4110.
62. Monzani F, Caraccio N, Meucci G, Lombardo F, Moscato G, Casolaro A, Ferdeghini M, Murri L, Ferrannini E 1999 Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis. Eur J Endocrinol 141:325-331.
63. Al-Humaidi MA 2000 Serum cytokines levels in Graves' disease. Saudi Med J 21:639-644.
64. Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, Wall JR, Roti E 2000 Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol 143:197-202.
65. Nygaard B, Jarlov AE, Kristensen LO, Faber J 2000 Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131 I-treatment of Graves' disease and nodular goiter. Horm Metab Res 32:283-287.
66. Burggraaf J, Lalezari S, Emeis JJ, Vischer UM, de Meyer PH, Pijl H, Cohen AF 2001 Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid 11:153-160.
67. Dimopoulou I, Ilias I, Mastorakos G, Mantzos E, Roussos C, Koutras DA 2001 Effects of severity of chronic obstructive pulmonary disease on thyroid function. Metabolism 50:1397-1401.
68. Bossowski A, Urban M 2001 Serum levels of cytokines in children and adolescents with Graves' disease and non-toxic nodular goiter. J Pediatr Endocrinol Metab 14:741-747.
69. Jurgilewicz DH, Rogowski F, Lebkowska U, Citko A, Jaroszewicz E, Parfienczyk A 2002 E-selectin, L-selectin, ICAM-1 and IL-6 concentrations changes in the serum of patients with hyperthyroidism in the early period of radioiodine I-131 therapy. Nucl Med Rev Cent East Eur 5:39-42.
70. Wahrenberg H, Wennlund A, Hoffstedt J 2002 Increased adipose tissue secretion of interleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves' hyperthyroidism. Eur J Endocrinol 146:607-611.
71. Senturk T, Kozaci LD, Kok F, Kadikoylu G, Bolaman Z 2003 Proinflammatory cytokine levels in hyperthyroidism. Clin Invest Med 26:58-63.
72. Pichler R, Maschek W, Hatzl-Griesenhofer M, Huber H, Crespillo-Gomez C, Berg J 2003 Soluble tumour necrosis factor-alpha receptor I and interleukin-6 as markers of activity in thyrotoxic Graves' disease. Horm Metab Res 35:427-433.
73. Molashenko NV, Sviridenko NIu, Platonova NM, Kolesnikova GS, Golitsyn SP, Bakalov SA, Serdiuk SE, Masenko VP, Domogadskii SP 2004 [The specific features of thyrotoxicosis and euthyroid hyperthyroxinemia developed due to the use of cordarone]. Klin Med (Mosk) 82:35-39.
74. Karanikas G, John P, Wahl K, Schuetz M, Dudczak R, Willheim M 2004 T-lymphocyte cytokine production patterns in nonimmune severe hypothyroid state and after thyroid hormone replacement therapy. Thyroid 14:488-492.
75. Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L, Ferrannini E, Salvetti A, Monzani F 2006 Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis. J Clin Endocrinol Metab 91:5076-5082.
76. Modzelewska A, Szelachowska M, Zonenberg A, Abdelrazek S, Nikolajuk A, Gorska M 2006 [Selected markers of endothelial dysfunction in patients with subclinical and overt hyperthyroidism]. Endokrynol Pol 57:202-210.
77. Zonenberg A, Telejko B, Szelachowska M, Modzelewska A, Nikolajuk A, Gorska M 2006 [Markers of endothelial dysfunction in patients with iodine induced hyperthyroidism]. Endokrynol Pol 57:210-217.
78. Sekeroglu MR, Altun ZB, Algun E, Dulger H, Noyan T, Balaharoglu R, Ozturk M 2006 Serum cytokines and bone metabolism in patients with thyroid dysfunction. Adv Ther 23:475-480.
79. Papanas N, Papazoglou D, Papatheodorou K, Antonoglou C, Kotsiou S, Maltezos E 2006 Thyroxine replacement dose in patients with Hashimoto disease: a potential role for interleukin-6. Cytokine 35:166-170.
80. Chopra IJ, Sakane S, Teco GN 1991 A study of the serum concentration of tumor necrosis factor-alpha in thyroidal and nonthyroidal illnesses. J Clin Endocrinol Metab 72:1113-1116.
81. Akalin A, Colak O, Alatas O, Efe B 2002 Bone remodelling markers and serum cytokines in patients with hyperthyroidism. Clin Endocrinol (Oxf) 57:125-129.
82. Diez JJ, Hernanz A, Medina S, Bayon C, Iglesias P 2002 Serum concentrations of tumour necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin Endocrinol (Oxf) 57:515-521.